Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical bacillus Calmette-Guérin treatment

Keyphrases

• Placebo 100%
• Randomized Controlled Trial 100%
• Urinary Symptoms 100%
• Extended Release 100%
• Bacillus Calmette 100%
• Intravesical 100%
• Oxybutynin 100%
• Urination 42%
• Treatment Group 28%
• No Significant Difference 28%
• Fever 28%
• Constipation 28%
• Dry Mouth 28%
• Urinary Frequency 28%
• Flu-like 28%
• Between-group 14%
• Baseline Scores 14%
• Bladder Pain Syndrome 14%
• Recurrence Rate 14%
• Nave 14%
• Arthralgia 14%
• Blurred Vision 14%
• Hematuria 14%
• Treatment Side Effects 14%
• Adverse Reactions 14%
• Symptom Prevalence 14%
• Medication Side Effects 14%
• Point Score 14%
• Treatment Tolerance 14%
• Systemic Symptoms 14%
• Invasive Urothelial Carcinoma 14%
• Repeated Measures Modeling 14%
• Linear Mixture 14%
• Irritative 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Symptom 100%
• Randomized Controlled Trial 100%
• Oxybutynin 100%
• Bacilli 100%
• Side Effect 25%
• Flu Like Syndrome 25%
• Constipation 25%
• Burn 25%
• Xerostomia 25%
• Adverse Event 12%
• Arthralgia 12%
• Recurrence Risk 12%
• Hematuria 12%
• Transitional Cell Carcinoma 12%
• Cholinergic Receptor Blocking Agent 12%
• Cystalgia 12%
• Blurred Vision 12%